Haematologica
HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
QUICK SEARCH:   [advanced]


     

Haematologica, Vol 92, Issue 9, 1268-1269 doi:10.3324/haematol.11202
Copyright © 2007 by Ferrata Storti Foundation
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Palmisano, M.
Right arrow Articles by Martinelli, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Palmisano, M.
Right arrow Articles by Martinelli, G.

Acute Myeloid Leukemia

NPM1 mutations are more stable than FLT3 mutations during the course of disease in patients with acute myeloid leukemia

Michela Palmisano, Tiziana Grafone, Emanuela Ottaviani, Nicoletta Testoni, Michele Baccarani, Giovanni Martinelli

Institute of Hematology and Medical Oncology "L. e A. Seràgnoli", S. Orsola-Malpighi Hospital, University of Bologna, Italy

Correspondence: Giovanni Martinelli, MD, Institute of Hematology and Medical Oncology "L. and A. Seràgnoli", S. Orsola-Malpighi Hospital, Via Massarenti 9, 40138 Bologna, Italy. Phone: international +39.051.6363829. Fax: international +39.051.6364037. E-mail: gmartino{at}kaiser.alma.unibo.it

NPM1 mutations have been reported to be the most frequent mutations in acute myeloid leukemia (AML). They are associated with a wide spectrum of morphologic subtypes of AML, normal karyotype and FLT3 mutations. The high frequency of NPM1 mutations might provide a suitable marker for monitoring residual disease of AML.

Key words: AML, FLT3 mutation, NPM1 mutation, minimal residual disease.




This article has been cited by other articles:


Home page
 haematolHome page
G. Meloni, M. Mancini, V. Gianfelici, M. P. Martelli, R. Foa, and B. Falini
Late relapse of acute myeloid leukemia with mutated NPM1 after eight years: evidence of NPM1 mutation stability
Haematologica, February 1, 2009; 94(2): 298 - 300.
[Full Text] [PDF]

Home page
 J. Mol. Diagn.Home page
G. Wertheim and A. Bagg
Nucleophosmin (NPM1) Mutations in Acute Myeloid Leukemia: An Ongoing (Cytoplasmic) Tale of Dueling Mutations and Duality of Molecular Genetic Testing Methodologies
J. Mol. Diagn., May 1, 2008; 10(3): 198 - 202.
[Abstract] [Full Text] [PDF]

Home page
 J. Mol. Diagn.Home page
P. Szankasi, M. Jama, and D. W. Bahler
A New DNA-Based Test for Detection of Nucleophosmin Exon 12 Mutations by Capillary Electrophoresis
J. Mol. Diagn., May 1, 2008; 10(3): 236 - 241.
[Abstract] [Full Text] [PDF]

Home page
 haematolHome page
B. Falini, M. P. Martelli, C. Mecucci, A. Liso, N. Bolli, B. Bigerna, A. Pucciarini, S. Pileri, G. Meloni, M. F. Martelli, et al.
Cytoplasmic mutated nucleophosmin is stable in primary leukemic cells and in a xenotransplant model of NPMc+ acute myeloid leukemia in SCID mice
Haematologica, May 1, 2008; 93(5): 775 - 779.
[Abstract] [Full Text] [PDF]

Home page
 haematolHome page
B. Falini, C. Mecucci, G. Saglio, F. L. Coco, D. Diverio, P. Brown, F. Pane, M. Mancini, M. P. Martelli, S. Pileri, et al.
NPM1 mutations and cytoplasmic nucleophosmin are mutually exclusive of recurrent genetic abnormalities: a comparative analysis of 2562 patients with acute myeloid leukemia
Haematologica, March 1, 2008; 93(3): 439 - 442.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
Copyright © 2007 by the Ferrata Storti Foundation.